Clinical trials: Antithrombotic
LVAD (Left Ventricular Assist Device) Thrombosis, LVAD
STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump
This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to…
- Conditions
- LVAD (Left Ventricular Assist Device) Thrombosis, LVAD, LVAD (Left Ventricular Assist Device), LVAD-related GI Bleed
- Trial name
- STAR (NCT07644247)
- Testing
- Warfarin (INR 2-3) with aspirin
- Volunteers
- 370 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Disease
High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department
This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or…
- Trial name
- NCT07278648
- Testing
- Antithrombotic therapy
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Cardiac Disease
Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization
Aim(s)/Objective(s) To evaluate the safety and efficacy of triple antithrombotic therapy in patients taking DAPT of aspirin and a P2Y12 inhibitor in addition to either a NOAC or warfarin for the prevention of thromboembolic or…
- Trial name
- NCT03889574
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Methodist Health System
Adverse Effect of Antithrombotic Drugs
Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate
This is a phase I clinical trial in healthy volunteers comparing the effect of lysine acetylsalicylate or aspirin on platelet function.
- Trial name
- ECCLIPSE (NCT02243137)
- Testing
- acetylsalicylic acid, prasugrel, lysine acetylsalicylate
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- David Vivas
Atrial Fibrillation
ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years
Lifelong oral anticoagulant (OAC) therapy is the preferred treatment for the prevention of thromboembolic events in the majority of patients with Atrial Fibrillation (AF).
- Trial name
- NCT04532528
- Testing
- Dabigatran
- Where
- 23 sites in Taiwan
- Volunteers
- 897 people
- Sponsor
- Boehringer Ingelheim
Individuals With a Disease of Cardiovascular System
Pharmacogenomics of Antithrombotic Drugs -a Register Linkage Study With National Registries and Biobanks in Finland
This is a retrospective cohort study linking data from Finnish Biobanks (Helsinki Biobank, Auria Biobank and THL Biobank), laboratory databases, and national registries of Social Insurance Institution of Finland (Kela) and the…
- Trial name
- NCT04001166
- Testing
- Non-interventional study
- Where
- Finland
- Volunteers
- 7,005 people, healthy volunteers welcome
- Sponsor
- VTT Technical Research Centre of Finland
Atrial Fibrillation (AF), Coronary Artery Disease
OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation
The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter…
- Conditions
- Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent
- Trial name
- OPTIA-AF (NCT07496281)
- Testing
- Oral anticoagulation, Single antiplatelet therapy
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Ewha Womans University Mokdong Hospital
COVID-19, Pneumonia
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)
Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host inflammatory response and activation of coagulation pathways.
- Trial name
- ATTACC (NCT04372589)
- Testing
- Heparin
- Where
- 60 sites in United States, Brazil and 2 more
- Volunteers
- 1,200 people
- Sponsor
- University of Manitoba
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Peripheral Artery Disease
REGistry of Long-term AnTithrombotic TherApy-1
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes
- Trial name
- REGATTA-1 (NCT04347200)
- Testing
- Antiplatelet Drug
- Where
- Russia
- Volunteers
- 2,000 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Ischemic Stroke, Intracranial Atherosclerosis
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for…
- Trial name
- CATIS-ICAS (NCT07468448)
- Testing
- Rivaroxaban, ASA
- Volunteers
- 1,172 people
- Sponsor
- Population Health Research Institute
Acute Ischemic Stroke, Cancer
A Prospective Study to Observe Clinical Outcomes in Patients Receiving Antiplatelet or Anticoagulant Therapy for Cancer-Associated Acute Ischemic Stroke
The goal of this observational study is to learn about the effectiveness and safety of antiplatelet and anticoagulant treatments in people with a history of cancer who have acute ischemic stroke.
- Trial name
- NCT07845903
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xuanwu Hospital, Beijing
Coronary Artery Disease
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
High on-treatment platelet reactivity (HOPR) is associated with increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI).
- Trial name
- OPTIMA-2 (NCT01955200)
- Testing
- Clopidogrel, Cilostazol, Ticagrelor
- Where
- China
- Volunteers
- 1,724 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Community-acquired Pneumonia
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs.
- Trial name
- ATTACC-CAP (NCT05848713)
- Testing
- Heparin
- Where
- 68 sites in United States, Brazil and 2 more
- Volunteers
- 4,000 people
- Sponsor
- University of Manitoba
Uterine Hemorrhage, Cardiovascular Diseases
A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular Surgery
This study aims to investigate uterine bleeding during menstruation in women taking antithrombotic medications after cardiac surgery.
- Conditions
- Uterine Hemorrhage, Cardiovascular Diseases, Antithrombotic Drugs
- Trial name
- NCT07870941
- Testing
- antithrombotic drugs
- Where
- China
- Volunteers
- 1,308 people
- Sponsor
- Shanghai Zhongshan Hospital
Atrial Fibrillation, Coronary Artery Disease
Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study
The purpose of the study is to evaluate non-inferiority of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and prior (>12 months) coronary stenting.
- Trial name
- OAC-ALONE (NCT01962545)
- Testing
- OAC alone
- Where
- Japan
- Volunteers
- 690 people
- Sponsor
- Satoshi Shizuta
Neuromuscular Blockade, Arthroplasty, Replacement, Hip
Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)
This study will assess the effect of reversal of neuromuscular blockade with sugammadex compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of post-surgical bleeding events and on…
- Conditions
- Neuromuscular Blockade, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Blood Coagulation
- Trial name
- NCT01422304
- Testing
- Sugammadex, neostigmine and glycopyrrolate or atropine
- Volunteers
- 1,198 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome
EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs
This registry has the aim to assess the use of different antithrombotic therapies, including untested drug combinations, routinely used during the hospitalization phase, with their timing, route and dose of administration, in…
- Trial name
- EYESHOT-2 (NCT06316128)
- Where
- 189 sites in Italy
- Volunteers
- 2,806 people
- Sponsor
- Heart Care Foundation
Atrial Fibrillation, Coronary Artery Disease
LAAO With DAPT Versus Antithrombotic Therapy
This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation…
- Trial name
- NCT03310801
- Testing
- ACP or Watchman
- Volunteers
- 480 people
- Sponsor
- Korea University Anam Hospital
Hemorrhage, Surgical, Hemorrhage Postoperative
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
- Conditions
- Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
- Trial name
- STAR-D (NCT05093504)
- Testing
- DrugSorb-ATR system
- Where
- 27 sites in United States
- Volunteers
- 9 people
- Sponsor
- CytoSorbents, Inc